Clinical reference Biomarker Directory
Back to directory

Intact Fibroblast Growth Factor 23

Established

FGF23 excess causes rare hypophosphatemic bone diseases, now treated with a monoclonal antibody built to block it.

Also known as FGF23
In plain language

FGF23 controls how much phosphate the body keeps versus loses in urine. Too much of it causes rare bone-softening diseases. A newer drug, burosumab, was specifically designed to block this hormone directly — a good example of a biomarker becoming its own drug target.

Biomarker & context

Fibroblast growth factor 23 (FGF23) is a bone-derived hormone that regulates phosphate balance by promoting renal phosphate excretion and suppressing active vitamin D production.

What it indicates

Excess FGF23 causes X-linked hypophosphatemia (XLH), the most common inherited cause of FGF23-related hypophosphatemic rickets, and tumor-induced osteomalacia (TIO), a rare acquired condition from FGF23-secreting mesenchymal tumors.

Diagnosis & clinical testing

Measured via serum immunoassay; TIO diagnosis is complicated by the difficulty of localizing the causative tumors, which are often small and hard to find even with extensive imaging, sometimes delaying diagnosis for years.

Guiding treatment

Burosumab, a monoclonal antibody that directly neutralizes FGF23, is now recommended first-line for XLH and is also FDA-approved for TIO — a rare case of a hormone-level biomarker having a drug built specifically to block it, replacing older, less effective oral phosphate and vitamin D supplementation.

Clinical significance

TIO diagnosis remains genuinely difficult due to challenges localizing small, hard-to-find causative tumors.

References
  1. Orphanet Journal of Rare Diseases. (2025). X-linked hypophosphatemia and tumor-induced osteomalacia: diagnostic and therapeutic challenges in the era of burosumab.